CREON® (pancrelipase) delayed-release capsules are indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.
Please see full Prescribing Information.
US-CREO-230452
References: 1. CREON [package insert]. AbbVie Inc. 2. Data on file, AbbVie Inc. Source: 2026 Commercial and Medicare Part D CREON and PERT access data. March 2026. 3. Data on file. AbbVie, Inc. 2026 Combined commercial and Medicare Part D CREON and PERT access data. March 2026. 4. Pezzilli R, Andriulli A, Bassi C, et al; Exocrine Pancreatic lnsufficiency collaborative Group. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. World J Gastroenrerol. 2013:19(44):7930-7946. 5. Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9(2):116-122. doi:10.1007/s11894-007-0005-4 6. Centers for Disease Control and Prevention. ICD-10 Coordination and Maintenance Committee Meeting. https://www.cdc.gov/nchs/data/icd/March-2022-topic-packet-Final.1.pdf. Accessed November 12, 2025.